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Abstract
Objective
To compare the incidence of noncommunicable diseases between adults with and without
cerebral palsy (CP).
Methods
A cohort study was conducted using primary care data from the Clinical Practice Research
Datalink. Cox models, stratiﬁed by matched set and adjusted for potential confounders, were
ﬁtted to compare the risk of any noncommunicable disease, cancer, cardiovascular disease, type
2 diabetes mellitus, and respiratory disease between adults with and without CP.
Results
The analysis included 1,705 adults with CP and 5,115 age-, sex-, and general practice–matched
adults without CP. There was evidence from adjusted analyses that adults with CP had 75%
increased risk of developing any noncommunicable disease compared to adults without CP
(hazard ratio [HR] 1.75, 95% conﬁdence interval [CI] 1.58–1.94). Speciﬁcally, they had
increased risk of cardiovascular disease (HR 1.76, 95% CI 1.48–2.11) and respiratory disease
(HR 2.61, 95% CI 2.14–3.19). There was no evidence of increased risk of cancer or type 2
diabetes mellitus.
Conclusions
Adults with CP had increased risk of noncommunicable disease, speciﬁcally cardiovascular and
respiratory disease. These ﬁndings highlight the need for clinical vigilance regarding identiﬁ-
cation of noncommunicable disease in people with CP and further research into the etiology
and management of noncommunicable disease in this population.
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Cerebral palsy (CP) is characterized by abnormal ﬁne and
gross motor functioning.1,2 People with CP may also experi-
ence comorbid conditions such as intellectual disability (ID),
epilepsy, and visual and hearing impairment.1,3–5 While sub-
stantial improvements were observed in survival among
children with CP between 1983 and 2010, survival among
adolescents and adults with CP who are 15 to 60 years of age
and feed orally and all adults with CP >60 years of age did not
improve at the same rate as survival in the general pop-
ulation.6 Several factors associated with CP may contribute to
this widening gap in survival, including severity of motor
impairments and presence of epilepsy, ID, musculoskeletal
disorders, and mental health disorders.7–11 An elevated risk of
noncommunicable disease (NCD) among people with CP
may also explain this widening gap.
NCD, particularly cardiovascular disease, cancer, respiratory
disease, and diabetes mellitus, is a leading cause of premature
mortality worldwide.12 Physical inactivity, which is known to
be prevalent among people with CP,13 is a shared and mod-
iﬁable risk factor for these conditions.14,15 Evidence for the
metabolic consequences of physical inactivity among people
with spinal cord injury prompted comparison to people with
CP,16 leading to the hypothesis that a negative cycle of
physical inactivity, accelerated loss of muscle mass, reduced
cardiorespiratory ﬁtness, and worsening mobility contributes
to elevated risk of NCD in people with CP.17
While there is evidence that adults with CP have increased risk
of NCD-related mortality, speciﬁcally mortality due to car-
diovascular disease, respiratory disease, and cancer, compared
to the general population,18–20 there is less evidence for the
relative risk of NCD among adults with CP. In 2015, a cross-
sectional study identiﬁed that adults with CP in the United
States had higher odds of cardiovascular and chronic re-
spiratory disease, but not diabetes mellitus, compared to
adults without CP.21 However, this study was limited by re-
liance on self-reported data, a potentially unrepresentative
population of adults with CP, and controls who were not
matched to adults with CP. A second cross-sectional study
conducted in the United States identiﬁed higher odds of
cardiometabolic, but not pulmonary, morbidity among young
adults with CP compared to adults without CP.22 Because
cardiometabolic morbidity was deﬁned as the presence of one
of a number of conditions, including hyperlipidemia, this
study did not provide information on the risk of speciﬁc
NCDs such as heart failure, ischemic heart disease, asthma,
cancer, or diabetes mellitus among adults with CP. The only
study to date to examine the risk of NCD among adults with
CP outside of the United States reported an increased risk of
stroke among adults with CP in Taiwan.23 However, the
authors did not explore the risk of other NCDs such as re-
spiratory disease, diabetes mellitus, and cancer.
There is a widening gap in life expectancy between some
adults with CP and the general population, which may be
explained by an increased risk of NCD. While a higher risk of
cardiovascular disease and chronic respiratory disease was
identiﬁed among adults with CP in the United States,21 such
a study exploring the risk of numerous NCDs has not been
replicated outside of the United States. Furthermore, while
there is evidence that adults with CP have a higher risk of
mortality due to cancer, no study has examined the relative
risk of cancer in adults with CP to date. This study aimed to
compare the rate of NCDs, namely cardiovascular disease,
chronic respiratory disease, cancer, and diabetes mellitus,
between adults with and without CP in the United Kingdom.
Methods
Study design and data source
A matched cohort study was conducted using data from the
UK Clinical Practice Research Datalink (CPRD). The CPRD
contains primary care data routinely collected via electronic
health records from general practices across all regions of the
United Kingdom. The CPRD covers ≈7% of the UK pop-
ulation, and data are largely representative of the UK pop-
ulation in terms of age and sex.24,25 The CPRD includes data
on clinical events, prescriptions, preventive care, referrals,
hospital admissions, and lifestyle and anthropometric meas-
ures. Clinical diagnoses are recorded in general practices using
the Read clinical classiﬁcation system, which is a hierarchical
system of recording clinical data. Read codes, consisting of
letters and numbers, are recorded for each clinical diagnosis
and are accompanied by Read terms, which are a corre-
sponding written description of the condition. Data collection
began in 1987, and we used data obtained during the period
from January 1, 1987, to November 30, 2015.
Participants
Patients ≥18 years of age with at least 1 record of CP occur-
ring during the study period and research-standard follow-up
(i.e., follow-up meeting criteria developed by the CRPD to
determine whether data are of suﬃcient quality to be used in
research) were included. A list of 23 Read codes, which in-
cluded cerebral palsy, spastic cerebral palsy, and congenital
cerebral palsy, was used to identify patients with CP. Start of
follow-up (i.e., the index date) for patients with CP was the
Glossary
BMI = body mass index; CI = conﬁdence interval; COPD = chronic obstructive pulmonary disease; CP = cerebral palsy;
CPRD = Clinical Practice Research Datalink;GP = general practitioner;HR = hazard ratio; ID = intellectual disability;NCD =
noncommunicable disease.
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latest of the following: the date of registration with the general
practice, the date data were considered research standard, or
January 1 of the year in which the patient turned 18 years of
age. Patients with a record of CP were matched to 3 control
patients without CP on age (within 3 years in either di-
rection), sex, and practice. Matching on practice controlled
for practice-level socioeconomic status and between-practice
variations in general practitioner (GP) diagnostic behaviors.
The index date for control patients was set to the index date of
their matched case. Control patients had a complete history
for the duration of their case’s follow-up.
Outcomes
We examined the incidence of cancer, cardiovascular disease,
type 2 diabetes mellitus, and respiratory disease because these
4 NCDs account for 82% of NCD-related premature mor-
tality.12 Cancer was identiﬁed as a ﬁrst event of breast, co-
lorectal, lung, or prostate cancer. Breast, colorectal, lung, and
prostate cancer are consistently the most common cancer
sites, accounting for 52.8% of cancer registrations in England
in 2016.26 Cardiovascular disease was identiﬁed as a ﬁrst event
of heart failure, hypertensive disease, ischemic heart disease,
cerebrovascular disease, or other heart disease. Respiratory
disease was identiﬁed as a ﬁrst event of chronic obstructive
pulmonary disease (COPD) or asthma. Asthma was identiﬁed
using a previously validated list of Read codes.27 For other
diagnoses, when a validated list was not available, the Read
code dictionary was searched to identify Read terms per-
taining to all outcomes. Final code lists were reviewed by
a consultant cardiologist.
In addition, the following criteria were applied to identify
COPD and type 2 diabetes mellitus. A Read code for COPD,
ﬁrst recorded after the patient turned 35 years of age, was used
to identify COPD. Diabetes mellitus was identiﬁed by (1)
a code for a deﬁnite diabetes diagnosis, (2) a code for a pos-
sible diabetes diagnosis with a subsequent prescription for
oral antidiabetics, or (3) ≥2 diabetes drug prescriptions after
the start of follow-up. These criteria have been used to identify
diabetes mellitus sin a previous study using the CPRD.28
Because it is not always possible to distinguish between type 1
and type 2 diabetes mellitus from Read codes for diabetes
mellitus and when the type of diabetes mellitus is stated this
information may not be reliable,29 age at ﬁrst diagnosis, age at
ﬁrst treatment, and treatment received were used to classify
type of diabetes mellitus.28,30 Patients were identiﬁed as
having type 2 diabetes mellitus if they were >35 years of age at
the ﬁrst diabetes diagnosis or they received exclusively oral
antidiabetics after the age of 35 years.
Covariates
Smoking status (current smoker, ex-smoker, nonsmoker),
alcohol consumption (current drinker, ex-drinker, or non-
drinker), and body mass index (BMI) were identiﬁed. BMI
was identiﬁed using values for height, weight, and BMI
taken by the GP.31 When multiple records of BMI, smoking
status, and alcohol consumption were available, the earliest
record after the patient turned 18 years of age was used for
the analyses. Although the record may have been taken
before the start of research-standard follow-up, it was
deemed preferable to include these data to maximize the
available data. Records taken before research-standard
follow-up were removed in a sensitivity analysis. We calcu-
lated the mean yearly GP consultation rate for each patient
by dividing the total number of face-to-face or telephone
consultations during follow-up by the total number of years
of follow-up (i.e., start of follow-up to ﬁrst event of any NCD
or censoring).
Statistical analysis
For each outcome, patients were followed up to the earliest of
the following: transfer out of CPRD, end of study period,
practice last collection date, death, or ﬁrst event of the out-
come. Baseline characteristics of patients with and without CP
were described.
In the primary analysis, a separate Cox model with an un-
derlying age time scale, stratiﬁed by matched set, was ﬁtted for
each outcome (i.e., cancer, cardiovascular disease, type 2 di-
abetes mellitus, and respiratory disease).32 A stratiﬁed model
assumes that patients in each strata have a diﬀerent baseline
hazard but that all other exposures within each strata satisfy
the proportional hazards assumption. To determine the haz-
ard of experiencing any NCD, a Cox model stratiﬁed by
outcome type and matched set was ﬁtted to allow the baseline
hazard to vary by outcome type. Robust standard errors were
calculated for this model to account for the within-patient
dependency between failure times.33 In a secondary analysis,
the incidence of heart failure, hypertensive disease, ischemic
heart disease, cerebrovascular disease, other heart disease,
COPD, and asthma was compared between patients with and
without CP using Cox models stratiﬁed by matched set.
Initially, unadjusted Cox models were ﬁtted before adjust-
ment for smoking status, alcohol consumption, BMI, and
mean yearly GP consultation rate by including these variables
as predictor variables in the Cox model. We adjusted for
consultation rate because people with CP may be more likely
to have a higher consultation rate and a higher consultation
rate may be associated with diagnosis of an NCD. Multiple
imputation by chained equations was used to impute missing
data for BMI from a linear regression model. The procedure
was performed with the ice command in Stata (StataCorp,
College Station, TX). To avoid bias in the analysis models, the
imputation model included all predictor variables in the
outcomemodel, matching variables, outcomes, and additional
predictors of BMI.34 In addition to the event indicator, we
included the untransformed event or censoring time because
it was found to be one of the best of several approaches when
multiply imputing a single normal covariate.35 Forty imputed
datasets were generated.34 Boxplots of the observed and im-
puted data over the imputations were generated to identify
discrepancies between the observed and imputed datasets.
Estimates were combined with the use of the Rubin36 rules.
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Because the mechanism underlying missing records for
smoking status and alcohol consumption in primary care data
is likely to be missing not at random as opposed to missing at
random,37,38 multiple imputation is not appropriate for these
data. Missing data for smoking status are most likely per-
taining to ex-smokers and nonsmokers, and missing data for
alcohol consumption are most likely pertaining to current
drinkers.37,38 Therefore, smoking status was dichotomized as
current smokers and noncurrent smokers, with missing data
assumed to relate to non–current smokers as proposed by
Marston et al.37 Alcohol consumption was dichotomized as
current drinkers and non–current drinkers with missing
records assumed to pertain to current drinkers. Because this is
potentially a strong assumption, we conducted sensitivity
analyses to assess the impact of imputation of missing data on
eﬀect estimates and inference.
Subgroup analysis
People with ID have established risk factors for NCDs such as
obesity, physical inactivity, unhealthy eating behaviors, and an-
tipsychotic medication.39–42 Therefore, the association between
CP andNCDmay be explained by ID. Furthermore, people with
CP and ID are more likely to have epilepsy and sensory im-
pairment and to be nonambulatory compared to those with CP
without ID.43 Therefore, IDmay be considered a crude proxy for
severity of CP or complexity of the individual’s overall medical
condition. We conducted a subgroup analysis to examine
whether the association between CP andNCDwas explained by
presence of ID. Participants with ID were identiﬁed by at least 1
Read code for ID recorded during the study period. The primary
analysis was then repeated stratiﬁed by ID status to compare the
hazard of cancer, cardiovascular disease, type 2 diabetes mellitus,
and respiratory disease between patients with CP and ID and
theirmatched controls and between patients withCPwithout ID
and their matched controls.
Model checking and sensitivity analyses
The validity of the assumption of proportional hazards was
assessed by plotting scaled Schoenfeld residuals against time
for all models and including an interaction term between time
and each predictor variable in each model. Martingale resid-
uals were plotted against BMI and mean yearly GP con-
sultations to ensure that there was a linear association
between BMI, GP consultations, and each outcome. Three
sensitivity analyses were conducted: (1) missing data for
smoking status, alcohol consumption, and BMI were excluded
(complete case analysis); (2) missing data for smoking status
were recategorized as current smokers, and missing data for
alcohol consumption were recategorized as non–current
drinker; and (3) records of BMI, smoking status, and alcohol
intake taken before research-standard follow-up were
excluded.
Standard protocol approvals, registrations,
and patient consents
The CPRD has obtained research ethics approval from a Na-
tional Research Ethics Service Committee for observational
research using anonymized CPRD data. The protocol was
approved by the Independent Scientiﬁc Advisory Committee
for Medicines and Healthcare Products Regulatory Agency
Database Research (protocol No. 16_077 R2A).
Data availability
As a result of CPRD data governance, data obtained from the
CPRD are not available from the study authors. Applications
to access data may be made to the CPRD at cprd.com.
Results
After exclusions, 1,705 patients with at least 1 record of CP
who were at least 18 years old within the study period and
research-standard follow-up were identiﬁed and matched to
5,115 patients without CP for age, sex, and practice. Char-
acteristics of patients with and without CP at the start of
follow-up are reported in table 1. Fifty-three percent of
patients were male. The median age at the start of follow-up
was 29 years. Underweight was more prevalent and over-
weight and obesity were less prevalent among patients with
CP. A smaller proportion of patients with CP were current
smokers or current drinkers. Median follow-up time for
patients with CP ranged from 6.07 years (range 0.002–27.94
years) for cardiovascular disease to 7.15 years (range
0.04–27.94 years) for cancer. Median follow-up time for
patients without CP ranged from 9.25 years (range
0.008–27.94 years) for cardiovascular disease to 10.91 years
(range 0.05–28.01 years) for cancer.
There was evidence from unadjusted and adjusted analyses
that the risk of any NCD was higher among patients with CP
compared to patients without CP (table 2). Patients with CP
had a 75% increased risk of anyNCD (hazard ratio [HR] 1.75,
95% conﬁdence interval [CI] 1.58–1.94). Unadjusted HRs
showed evidence that patients with CP had a higher risk of
cardiovascular disease (HR 1.20, 95% CI 1.03–1.40) and re-
spiratory disease (HR 1.74, 95% CI 1.47–2.06) than patients
without CP. After adjustment for potential confounders, the
association between CP and cardiovascular disease (HR 1.76,
95% CI 1.48–2.11) and CP and respiratory disease (HR 2.61,
95% CI 2.14–3.19) remained. There was no evidence of in-
creased risk of cancer or type 2 diabetes mellitus from un-
adjusted or adjusted analyses.
For individual cardiovascular and respiratory diseases, un-
adjusted analyses showed evidence of association between CP
and heart failure (HR 2.37, 95% CI 1.47–3.84), cerebrovas-
cular disease (HR 3.46, 95% CI 2.14–5.60), and asthma (HR
1.31, 95% CI 1.11–1.56) (table 3). Adjusted analyses also
showed evidence of association between CP and heart failure
(HR 2.62, 95% CI 1.51–4.52), cerebrovascular disease (HR
5.53, 95% CI 3.04–10.06), and asthma (HR 2.24, 95% CI
1.82–2.76). There was no evidence from unadjusted analyses
that CP was associated with hypertensive disease (HR 1.08,
95% CI 0.91–1.28) or ischemic heart disease (HR 1.48, 95%
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Table 1 Participant characteristics at start of follow-up
Variable
Patients with CP
(n = 1,705)
Patients without CP
(n = 5,115)
Total
(n = 6,820)
Sex
Male 907 (53.2) 2,721 (53.2) 3,628 (53.2)
Age, y
Median (IQR), y 29 (20–42) 29 (20–42) 29 (20–42)
<30, n (%) 877 (51.4) 2,631 (51.4) 3,508 (51.4)
30–39, n (%) 336 (19.7) 1,008 (19.7) 1,344 (19.7)
40–49, n (%) 223 (13.1) 669 (13.1) 892 (13.1)
50–59, n (%) 135 (7.9) 405 (7.9) 540 (7.9)
≥60, n (%) 134 (7.9) 402 (7.9) 536 (7.9)
BMI, kg/m2
Mean (SD) 24.46 (6.58) 25.41 (5.17) 25.21 (5.50)
BMI categories,
kg/m2
<18, n (%) 109 (6.4) 75 (1.5) 184 (2.7)
18–24, n (%) 526 (30.9) 2,049 (40.1) 2,575 (37.8)
25–29, n (%) 232 (13.6) 1,210 (23.7) 1,442 (21.1)
≥30, n (%) 164 (9.6) 586 (11.5) 750 (11.0)
Missing, n (%) 674 (39.5) 1,195 (23.4) 1,869 (27.4)
Smoking status, n (%)
Current smoker 213 (12.5) 1,511 (29.5) 1,724 (25.3)
Ex-smoker 65 (3.8) 424 (8.3) 489 (7.2)
Nonsmoker 1,261 (74.0) 2,740 (53.6) 4,001 (58.7)
Missing 166 (9.7) 440 (8.6) 606 (8.9)
Alcohol consumption
Current drinker 724 (42.5) 3,142 (61.4) 3,866 (56.7)
Ex-drinker 15 (0.9) 40 (0.8) 55 (0.8)
Nondrinker 527 (30.9) 640 (12.5) 1,167 (17.1)
Missing 439 (25.8) 1,293 (25.3) 1,732 (25.4)
Practice regiona
North England and
Scotland
473 (27.7) 1,419 (27.7) 1,892 (27.7)
Midlands and Wales 603 (35.4) 1,809 (35.4) 2,412 (35.4)
South England 587 (34.4) 1,761 (34.4) 2,348 (34.4)
Northern Ireland 42 (2.5) 126 (2.5) 168 (2.5)
Mean yearly GP
consultations
Median (IQR) 6.03 (2.44–12.01) 2.32 (0.82–5.05) 2.89 (1.03–6.55)
Abbreviations: BMI = body mass index; CP = cerebral palsy; GP = general practitioner; IQR = interquartile range.
a North England and Scotland: Northeast England, Northwest England, Yorkshire, Scotland; Midlands. Wales: East Midlands, West Midlands, East of England,
Wales. South England: Southwest England, South Central England, London, Southeast England.
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CI 0.99–2.23). However, adjusted analyses showed evidence
of increased risk of hypertensive disease (HR 1.64, 95% CI
1.34–2.01) and ischemic heart disease (HR 2.32, 95% CI
1.45–3.71) among people with CP.
Subgroup analysis
Twenty-one percent (n = 363) of patients with CP had a re-
cord of ID (table 4). Six percent (n = 24) of patients without
CP had a record of ID; 10 were matched to patients with CP
and ID, and 14 were matched to patients with CP without ID.
We found evidence of increased risk of any NCD in patients
with CP both with and without ID (table 5). Adjusted anal-
yses showed evidence that patients with CPwithout ID had an
increased risk of cardiovascular disease and respiratory dis-
ease, but not of cancer or type 2 diabetes mellitus (table 5).
However, patients with CP and ID had increased risk of re-
spiratory disease only (table 5).
Sensitivity analyses
Complete case analysis resulted in identical conclusions, with
CIs including estimates obtained from the primary analysis
(table 6). Similarly, sensitivity analyses after recategorization
of missing data relating to smoking status and alcohol con-
sumption and use of research-standard data only for smoking
status, alcohol consumption, and BMI resulted in identical
conclusions.
Discussion
We found evidence of an increased risk of cardiovascular
disease and respiratory disease among adults with CP com-
pared to adults without CP but no evidence of increased risk
of cancer or type 2 diabetes mellitus. When we examined
individual cardiovascular and respiratory diseases, we found
an increased risk of heart failure, hypertensive disease, ische-
mic heart disease, cerebrovascular disease, and asthma among
adults with CP.
Our results are broadly supportive of previous ﬁndings from
a cross-sectional study conducted in the United States that
found that the odds of hypertension, stroke, other heart dis-
ease, asthma, and emphysema were between 1.3 and 2.0 times
higher among adults with CP compared to the general pop-
ulation.21 In accordance with our ﬁndings, there was no in-
creased risk of diabetes mellitus among adults with CP.21 A
more recent cross-sectional study found that young adults
with CP had higher odds of cardiometabolic morbidity
compared to adults without CP (odds ratio 1.98, 95% CI
Table 2 Incidence rate and unadjusted and adjustedHRs forNCDs comparing patientswith CP to patientswithout CP (n =
6,820)
Events, n (%)
Person-years,
×1,000
Incidence, per 1,000
person-y
Unadjusted HR
(95% CI) p Value
Adjusted HRa
(95% CI) p Value
Cancer
CP 15 (0.88) 14.5 1.03 0.99 (0.55–1.78) 0.980 1.35 (0.71–2.56) 0.362
Non-CP 83 (1.62) 56.4 1.47 1 1
Type 2
diabetes mellitus
CP 47 (2.76) 14.4 3.26 0.89 (0.64–1.23) 0.481 1.06 (0.71–1.59) 0.774
Non-CP 214 (4.18) 55.4 3.86 1 1
All cardiova
scular disease
CP 248 (14.6) 13.1 19.0 1.20 (1.03–1.40) 0.021 1.76 (1.48–2.11) <0.001
Non-CP 815 (15.9) 50.5 16.1 1 1
Respiratory
disease
CP 215 (12.6) 14.3 15.0 1.74 (1.47–2.06) <0.001 2.61 (2.14–3.19) <0.001
Non-CP 650 (12.7) 55.3 11.8 1 1
Any NCD
CP — — — 1.20 (1.09–1.32) <0.001 1.75 (1.58–1.94) <0.001
Non-CP — — — 1 1
Abbreviations: CI = confidence interval; CP = cerebral palsy; HR = hazard ratio; NCD = noncommunicable disease.
a Adjusted for smoking status, alcohol consumption, body mass index, and mean yearly general practitioner consultations.
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1.26–3.13), but not of pulmonary morbidity.22 However, the
ﬁndings are not directly comparable because cardiometabolic
morbidity was deﬁned as the presence of at least one of several
conditions, including type 2 diabetes mellitus, impaired glu-
cose tolerance, and hyperlipidemia. Similarly, pulmonary
morbidity was deﬁned as a diagnosis of asthma, pulmonary
embolism, or emphysema, so it is not possible to directly
compare the results between studies. The HR for stroke in our
study was higher than that observed in a cohort study in
Taiwan, which found a 2-fold increased risk of stroke among
people with CP compared to people without CP.23 Diﬀer-
ences may have resulted because we controlled for smoking
status, alcohol consumption, and BMI, which potentially
confound the association between CP and stroke.
Although no study has compared the risk of cancer between
adults with and without CP, 3 cohort studies have examined
the risk of mortality due to cancer among adults with CP with
inconsistent results. Two studies reported an increased risk of
cancer-related mortality among adults with CP in
California,18,19 and a third reported no increased risk among
English adults with CP.20We similarly found no increased risk
of cancer among adults with CP. Diﬀerences in results may be
due to diﬀerences in the risk of cancer between CP
Table 3 Incidence rate and unadjusted and adjusted HRs for each cardiovascular and respiratory disease comparing
patients with CP to patients without CP (n = 6,820)
Events, no.
(%)
Person-years,
×1,000
Incidence, per 1,000
person-y
Unadjusted HR
(95% CI)
p
Value
Adjusted HRa
(95% CI)
p
Value
Cardiovascular
disease
Heart failure
CP 30 (1.76) 14.5 2.07 2.37 (1.47–3.84) <0.001 2.62 (1.51–4.52) 0.001
Non-CP 69 (1.35) 56.5 1.22 1 1
Hypertensive
disease
CP 187 (10.97) 13.4 13.98 1.08 (0.91–1.28) 0.398 1.64 (1.34–2.01) <0.001
Non-CP 676 (13.22) 51.7 13.08 1 1
Ischemic heart
disease
CP 35 (2.05) 14.4 2.43 1.48 (0.99–2.23) 0.057 2.32 (1.45–3.71) <0.001
Non-CP 108 (2.11) 55.9 1.93 1 1
Cerebrovascular
disease
CP 36 (2.11) 14.5 2.48 3.46 (2.14–5.60) <0.001 5.53 (3.04–10.06) <0.001
Non-CP 76 (1.49) 56.5 1.34 1 1
Other heart
diseases
CP 25 (1.47) 14.5 1.72 0.84 (0.54–1.32) 0.457 1.07 (0.66–1.71) 0.790
Non-CP 131 (2.56) 56.1 2.34 1 1
Respiratory disease
COPD
CP 38 (2.23) 14.3 2.65 0.88 (0.61–1.27) 0.498 1.34 (0.89–2.02) 0.165
Non-CP 171 (3.34) 55.3 3.09 1 1
Asthma
CP 197 (11.55) 13.3 14.8 1.31 (1.11–1.56) 0.002 2.24 (1.82–2.76) <0.001
Non-CP 534 (10.44) 52.2 10.2 1 1
Abbreviations: CI = confidence interval; COPD = chronic obstructive pulmonary disease; CP = cerebral palsy; HR = hazard ratio.
a Adjusted for smoking status, alcohol consumption, body mass index, and mean yearly general practitioner consultations.
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populations in the United States and United Kingdom. Al-
ternatively, the discrepancy may have resulted because we
deﬁned cancer as the presence of cancer at 1 of 4 sites in our
analysis (i.e., breast, colorectal, lung, or prostate). A cohort
study in the United States found that adults with CP had
a higher risk of death due to breast and colon cancer but not
due to lung or prostate cancer,19 suggesting that the associ-
ation between CP and cancer may be site speciﬁc. We were
unable to examine risk by cancer site because we observed
a relatively small number of cancer events in our sample.
Table 4 Patient characteristics at start of follow-up stratified by ID
Variable
Patients with CP
and ID (n = 363)
Patients without CP matched to
patients with CP and ID (n = 1,089)
Patients with CP
without ID (n = 1,342)
Patients without CP matched to
patients with CP without ID (n = 4,026)
Sex
Male 204 (56.2) 612 (56.2) 703 (52.4) 2,109 (52.4)
Age, y
Median (IQR) 29 (21–40) 29 (21–40) 29 (20–43) 29 (20–43)
<30, n (%) 186 (51.2) 558 (51.2) 691 (51.5) 2073 (51.5)
30–39, n (%) 84 (23.1) 252 (23.1) 252 (18.8) 756 (18.8)
40–49, n (%) 51 (14.1) 153 (14.1) 172 (12.8) 516 (12.8)
50–59, n (%) 27 (7.4) 81 (7.4) 108 (8.1) 324 (8.1)
≥60, n (%) 15 (4.1) 45 (4.1) 119 (8.9) 357 (8.9)
BMI, kg/m2
Mean (SD) 24.32 (6.92) 25.40 (5.21) 24.50 (6.49) 25.41 (5.15)
Range 6.10–51.25 16.06–54.60 11.47–80.00 5.9–63.71
<18, n (%) 33 (9.1) 15 (1.4) 76 (5.7) 60 (1.5)
18–24, n (%) 102 (28.1) 459 (42.2) 424 (31.6) 1,590 (39.5)
25–29, n (%) 39 (10.7) 261 (24.0) 193 (14.4) 949 (23.6)
≥30, n (%) 45 (12.4) 125 (11.5) 119 (8.9) 461 (11.5)
Missing, n (%) 144 (39.7) 229 (21.0) 530 (39.5) 966 (24.0)
Smoking status,
n (%)
Current
smoker
19 (5.2) 360 (33.1) 194 (14.5) 1,151 (28.6)
Ex-smoker 5 (1.4) 96 (8.8) 60 (4.5) 328 (9.3)
Nonsmoker 318 (87.6) 568 (52.2) 943 (70.3) 2,172 (54.0)
Missing 21 (5.8) 65 (6.0) 145 (10.8) 375 (9.3)
Alcohol
consumption, n
(%)
Current
drinker
123 (33.9) 699 (64.2) 601 (44.8) 2,443 (60.7)
Ex-drinker 2 (0.6) 4 (0.4) 13 (1.0) 36 (0.9)
Nondrinker 180 (49.6) 136 (12.5) 347 (25.9) 504 (12.5)
Missing 58 (16.0) 250 (23.0) 381 (28.4) 1,043 (25.9)
Mean yearly GP
consultations, n
Median (IQR) 8.87 (4.50–16.24) 2.45 (0.98–5.10) 5.40 (2.20–10.70) 2.28 (0.78–5.03)
Abbreviations: BMI = body mass index; CP = cerebral palsy; GP = general practitioner; ID = intellectual disability; IQR = interquartile range.
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While our results demonstrate an elevated risk of NCD
among adults with CP, speciﬁcally cardiovascular disease and
chronic respiratory disease, they do not elucidate mechanisms
for this elevated risk. The prevalence of smoking and alcohol
consumption was lower among adults with CP compared to
adults without CP. Similarly, the prevalence of obesity was
lower among adults with CP. However, it is possible that BMI
as a metric lacks the sensitivity to detect high levels of body fat
because people with CP have a lower proportion of lean body
mass.44 Thus, BMI may be a poor indicator of metabolic risk
factors such as hyperlipidemia in adults with CP,45,46 and poor
cardiovascular outcomes may occur among people with CP at
lower BMI cutoﬀ points than those applied to the general
population. Other potential factors driving the association
between CP and increased rate of NCD may include physical
inactivity and inadequate management of risk factors for
NCD such as hyperlipidemia. While 1 study found that
women with CP and ID were less likely to receive a mam-
mogram compared to women with other causes of ID, no
research has examined the management of NCD among
Table 5 Incidence rate and unadjusted and adjusted HRs for NCDs comparing patients with CP and ID to matched
patients without CP (n = 1,452), and patients with CP without ID to matched patients without CP (n = 5,368)
Events, n (%) Person-years, ×1,000
Incidence,
per 1,000
person-y
Unadjusted
HR (95% CI) p Value Adjusted HRa (95% CI) p Value
Cancer
CP and ID —b —b —b 0.86 (0.18–4.13) 0.848 4.75 (0.33–69.3) 0.254
Non-CP —b —b —b 1 1
CP without ID 13 (0.97) 11.1 1.17 1.02 (0.54–1.91) 0.957 1.30 (0.66–2.55) 0.453
Non-CP 71 (1.8) 44.4 1.60 1 1
Type 2 diabetes
mellitus
CP and ID 10 (2.8) 3.4 2.94 1.00 (0.49–2.05) 1.000 0.86 (0.28–2.67) 0.793
Non-CP 34 (3.1) 12.0 2.85 1 1
CP without ID 37 (2.8) 11.0 3.36 0.86 (0.60–1.25) 0.432 1.08 (0.70–1.68) 0.715
Non-CP 180 (4.5) 43.5 4.14 1 1
Cardiovascular
disease
CP and ID 30 (8.3) 3.3 9.2 0.67 (0.45–1.00) 0.052 1.43 (0.84–2.43) 0.186
Non-CP 145 (13.3) 11.1 13.0 1 1
CP without ID 218 (16.2) 9.8 22.2 1.35 (1.14–1.59) <0.001 1.84 (1.52–2.23) <0.001
Non-CP 670 (16.6) 39.4 17.0 1 1
Respiratory
disease
CP and ID 35 (9.6) 3.4 10.3 1.33 (0.89–1.98) 0.166 2.36 (1.33–4.18) 0.003
Non-CP 131 (12.0) 12.0 10.9 1 1
CP without ID 180 (13.4) 10.9 16.5 1.85 (1.53–2.23) <0.001 2.64 (2.13–3.27) <0.001
Non-CP 519 (12.9) 43.3 12.0 1 1
Any NCD
CP and ID — — — 0.79 (0.59–1.07) 0.132 1.54 (1.08–2.18) 0.016
Non-CP 1 1
CP without ID — — — 1.30 (1.18–1.44) <0.001 1.79 (1.61–1.99) <0.001
Non-CP 1 1
Abbreviations: CI = confidence interval; CP = cerebral palsy; HR = hazard ratio; ID = intellectual disability; NCD = noncommunicable disease.
a Adjusted for smoking status, alcohol consumption, body mass index, and mean yearly general practitioner consultations.
b Data not reported because <5 events per cell.
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adults with CP without ID or speciﬁcally the management of
cardiovascular disease in adults with CP.13
CP is a heterogeneous condition in terms of severity of motor
impairment and presence of associated conditions. It is pos-
sible that the association between CP and NCD diﬀers
according to severity of motor impairment, including ambu-
latory and feeding status, and the presence of associated
conditions such as epilepsy and dysphagia. Although we did
not examine the causes of increased risk of NCD among
adults with CP, we did examine whether ID explained it. ID
may be considered a crude proxy for severity of CP in that it is
strongly associated with the presence of epilepsy and severity
of motor impairment; 83% of people with CP who are non-
ambulant and 78.6% of people with CP who have epilepsy
have ID.43 This suggests that the majority of people with CP
without ID in this analysis are likely to be ambulant and not to
have epilepsy. However, the risk of NCD was still elevated in
those without ID. We found that individuals with CP, both
with and without ID, had increased risk of chronic respiratory
disease, but the risk of cardiovascular disease was elevated
only among those without ID. No previous study has
examined whether the association between CP and NCD
diﬀers according to the presence of ID. However, a recent
meta-analysis found that the pooled prevalence of type 2 di-
abetes mellitus, cerebrovascular disease, and undeﬁned car-
diovascular disease was similar between people with ID and
the general population.47 The prevalence of ischemic heart
disease was found to be lower among people with ID.47 Given
that people with CP and ID are likely to have more severe
motor impairment and therefore reduced life expectancy
compared to those without ID,9 it is possible that they are
more likely to die of acute conditions such as pneumonia
before developing NCD. While there is clear evidence that
adults with CP have increased risk of NCD, speciﬁcally car-
diovascular disease and chronic respiratory disease, which is
not wholly explained by ID, further research is needed to
explore the etiology of NCD in CP.
The primary strength of our study is that it extends the current
evidence base by leveraging a large sample of adults with CP
to examine the incidence of a number of NCDs.17,22,23 The
sample was obtained from a dataset that includes data from
general practices across all regions of the United Kingdom
Table 6 Incidence rate and unadjusted and adjusted HRs for NCDs using patients with complete data for smoking status,
alcohol consumption, and BMI
Complete case analysis; all patientswith
CP compared to matched patients
without CP (n = 4,463)
Complete case analysis; patients with
CP and ID compared to matched
patients without CP
(n = 991)
Complete case analysis; patients with
CP without ID compared to matched
patients without CP
(n = 3,472)
Adjusted HRa
(95% CI) p Value
Adjusted HRa
(95% CI) p Value
Adjusted HRa
(95% CI) p Value
Cancer 1.68 (0.77–3.66) 0.194 Not estimable 1.66 (0.73–3.76) 0.224
Type 2 diabetes
mellitus
1.22 (0.74–2.00) 0.434 0.51 (0.13–2.09) 0.352 1.39 (0.81–2.40) 0.237
Cardiovascular
disease
1.85 (1.46–2.34) <0.001 1.92 (0.96–3.18) 0.064 1.86 (1.44–2.39) <0.001
Respiratory
disease
2.49 (1.92–3.24) <0.001 2.18 (1.07–4.45) 0.033 2.62 (1.97–3.47) <0.001
Any NCD 1.91 (1.67–2.17) <0.001 1.71 (1.08–2.71) 0.022 1.97 (1.72–2.24) <0.001
Heart failure 3.38 (1.44–7.91) 0.005 — —
Hypertensive
disease
1.94 (1.50–2.52) <0.001 — —
Ischemic heart
disease
2.18 (1.22–3.89) 0.008 — —
Cerebrovascular
disease
4.44 (1.77–11.17) 0.002 — —
Other heart
diseases
1.32 (0.70–2.51) 0.391 — —
COPD 1.95 (1.17–3.25) 0.010 — —
Asthma 2.31 (1.74–3.08) <0.001 — —
Abbreviations: BMI = body mass index; CI = confidence interval; COPD = chronic obstructive pulmonary disease; CP = cerebral palsy; HR = hazard ratio; ID =
intellectual disability; NCD = noncommunicable disease.
a Adjusted for smoking status, alcohol consumption, BMI, and mean yearly general practitioner consultations.
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and is largely representative of the UK population in terms of
age and sex. In addition, we used physician diagnosis of CP
and NCD, adjusted for several potential confounders, and
assessed the robustness of our ﬁndings to a number of sen-
sitivity analyses. There are also limitations to this study. We
did not have data on physical activity and severity of motor
impairment such as ambulatory status and feeding status.
Because these are likely mediators of the association between
CP and NCD, conditioning on them may induce bias.48
However, it is likely that the risk of NCD among the pop-
ulation of adults with CP diﬀers according to severity of motor
impairment. The inability to conduct stratiﬁed analysis
according to motor function, based on Gross Motor Function
Classiﬁcation System level, for example, is an important lim-
itation of this study that needs to be addressed in future
research. Consistent with previous studies of primary care
data,31,38 a substantial proportion of data were missing for
smoking status, alcohol consumption, and BMI. Because data
on smoking status and alcohol consumption in primary care
datasets may be missing not at random and not missing at
random,37,38 missing data were assumed to refer to non-
smokers and drinkers, respectively. While this is potentially an
incorrect assumption to make, complete case analysis and
recategorizing missing data to smokers and nondrinkers
resulted in no diﬀerence in the conclusions of the study. Fi-
nally, because patients were followed up beyond the occur-
rence of a ﬁrst event of any NCD, assuming that the ﬁrst event
is an absorbing event potentially wastes information. We
therefore chose to model the relationship between CP and
each outcome separately because it was of interest to examine
the association between CP and the ﬁrst event of speciﬁc
NCDs. However, although examining the association be-
tween CP and each NCD separately aids interpretation of the
relationship between CP and NCD and provides more clini-
cally relevant ﬁndings, the large number of analyses con-
ducted potentially increased the risk of a type I error.
This study highlights the increased risk of potentially pre-
ventable NCDs among adults with CP. The results are largely
consistent with previous evidence, which to date is primarily
from US populations. Our results provide strong evidence
that further research is needed to understand the causative
mechanisms of this increased risk and to improve targeted
interventions aimed at preventing NCDs among people
with CP.
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